AZILECT bulk active fine chemical sources

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
Hangzhou APIChem Technology	⤷ Get Started Free	AC-724	⤷ Get Started Free
Molport	⤷ Get Started Free	MolPort-005-937-324	⤷ Get Started Free
AKos Consulting & Solutions	⤷ Get Started Free	AKOS005145768	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 29, 2025

Introduction

Azilect (rasagiline mesylate) is a potent selective monoamine oxidase B (MAO-B) inhibitor indicated primarily for the treatment of Parkinson's disease (PD). As a critical therapeutic agent, its manufacturing relies heavily on the sourcing of high-quality active pharmaceutical ingredients (APIs). Given the centrality of APIs in ensuring drug efficacy, safety, and regulatory compliance, a thorough understanding of bulk API sources is vital for manufacturers, pharmaceutical stakeholders, and regulatory bodies. This article explores the global landscape of Bulk API providers for rasagiline mesylate, emphasizing quality standards, sourcing strategies, and industry trends.

Understanding Rasagiline Mesylate and Its Manufacturing Complexity

Rasagiline mesylate's synthesis involves intricate chemical processes demanding specific intermediates and high-purity starting materials. The manufacturing process includes asymmetric synthesis steps to achieve stereochemical specificity, underscoring the necessity for reliable raw material suppliers capable of consistent, pharmaceutical-grade outputs. The complexity inherently influences API sourcing strategies, with a focus on quality, regulatory approval, and supply chain robustness.

Global API Manufacturing Landscape

1. Leading API Producers and Geographical Distribution

The global API manufacturing sector for rasagiline mesylate is characterized by a handful of specialized chemical companies, primarily based in Asia, Europe, and North America. Top suppliers leverage advanced synthetic technologies combined with stringent quality systems aligned with Good Manufacturing Practices (GMP) standards.

Asia-Pacific Region: Dominates API production, accounting for approximately 55-65% of global API manufacturing capacity. Companies here benefit from lower production costs and expanding infrastructure. Notable players include China-based firms like Zhejiang Hisun Pharmaceutical Co., Ltd and Zhejiang Medicine Co., Ltd, known for their extensive portfolio in neurological APIs ([1]).
Europe: Hosts established pharmaceutical API manufacturers adhering to stringent regulatory standards, including Basel-based suppliers and companies in Germany and Switzerland, emphasizing high-quality output and innovative manufacturing processes ([2]).
North America: While relatively smaller in API production capacity for rasagiline, US and Canadian pharma API suppliers focus on compliance and supply security, partnering with CDMOs and multinational firms.

2. Key Suppliers of Rasagiline Mesylate API

Major API manufacturers with documented production of rasagiline mesylate include:

Zhejiang Hisun Pharmaceutical Co., Ltd [1]: Recognized for robust manufacturing capacity, quality assurance, and domestic and international regulatory approvals.
Shenzhen Biochem Co., Ltd: A notable Chinese supplier known for cost-effective API production aligned with international GMP standards.
Vasudha Pharma Chem Ltd (India): Offers high-quality APIs with extensive regulatory filings suitable for global markets.
SuRui Pharmaceutical Co., Ltd (China): Focuses on complex APIs with established export channels.

These companies are frequently listed in global procurement databases, such as the WHO Prequalification Program and Pharmacopoeial monographs, enhancing their credibility.

Quality Standards and Regulatory Compliance

API sourcing for AZILECT demands adherence to cGMP standards, with suppliers needing relevant certifications such as:

FDA approval or EUA for domestic production or export.
EMA certification for European regulatory compliance.
WHO prequalification for manufacturers targeting global access, particularly in developing markets.

Adherence to the pharmacopoeial standards (USP, EP) for rasagiline mesylate further ensures product sameness and safety.

Supply Chain Considerations

Reliability and consistency are key. Pharmaceutical companies prefer suppliers with:

Proven track record of uninterrupted supply.
Capabilities for large-scale production.
Strict adherence to quality control protocols, including in-process controls and final product testing.
Strong logistical networks and contingency plans to mitigate disruptions.

The ongoing COVID-19 pandemic highlighted vulnerabilities in concentrated supply chains, prompting a diversification strategy to include multiple API sources for critical drugs like AZILECT.

Emerging Trends in API Sourcing

Vertical Integration: Major pharmaceutical firms increasingly invest in captive API manufacturing to secure supply and meet quality demands.
Contract Manufacturing & Outsourcing: Growing reliance on CMO partnerships—mostly in Asia—to leverage cost efficiencies and technical expertise.
Regulatory Stringency: Stricter regulatory oversight compels suppliers to exceed quality benchmarks, fostering innovation in manufacturing processes.
Sustainability & Green Chemistry: Environmental considerations influence sourcing, with companies pursuing eco-friendly synthesis routes and sustainable raw material sources.

Conclusion

The sourcing of bulk API for AZILECT involves a complex, multi-faceted landscape epitomized by high-quality, reliable manufacturers predominantly based in Asia and Europe. Ensuring consistent supply and regulatory compliance remains paramount, particularly given the critical therapeutic role of rasagiline mesylate in Parkinson's treatment. Stakeholders must evaluate suppliers on quality standards, manufacturing capacity, regulatory standing, and supply chain resilience to mitigate risk and ensure patient safety.

Key Takeaways

Asia-Pacific dominates rasagiline API production, with Chinese suppliers leading due to cost advantages and capacity expansion.
European and North American suppliers emphasize regulatory compliance and quality assurance, suitable for high-standard markets.
Robust quality assurance measures, including cGMP certification and pharmacopoeial compliance, are non-negotiable in API sourcing.
Supply chain diversification is critical amid global disruptions, prompting manufacturers to engage multiple suppliers and consider vertical integration.
Emerging trends such as green chemistry and strategic outsourcing shape future API sourcing strategies, emphasizing sustainability and technical excellence.

FAQs

1. What are the primary criteria for selecting an API supplier for AZILECT?
Suppliers must demonstrate GMP compliance, quality certifications (FDA, EMA), capacity for large-scale production, proven track record, and logistical reliability.

2. How does the geographical origin of an API supplier influence regulatory approval?
Regulatory agencies scrutinize manufacturing standards; suppliers in regions with stringent regulatory frameworks (Europe, North America) often simplify approval processes, but Asian suppliers with approved manufacturing sites are increasingly meeting these standards through certifications.

3. Are there concerns related to API quality from Chinese manufacturers?
While some Chinese suppliers have faced scrutiny, many uphold rigorous quality standards, supported by international certifications. Verification through audits, certifications, and prior regulatory approvals is essential.

4. How does the complexity of rasagiline synthesis influence API sourcing?
Its asymmetric synthesis and stereochemical specificity demand highly controlled manufacturing processes, limiting sourcing options to specialized, technically advanced suppliers.

5. What future developments could impact API sourcing for AZILECT?
Advances in green chemistry, biotechnological synthesis, and supply chain digitization may enhance quality, sustainability, and resilience, influencing sourcing strategies.

References

[1] Global API Industry Reports, 2022.
[2] European Medicines Agency (EMA), API Manufacturer Listings, 2023.

Bulk Pharmaceutical API Sources for AZILECT